Rezolute (RZLT) Corporate Presentation summary

Company overview and strategy

• Focuses on treating severe hypoglycemia caused by all forms of hyperinsulinism (HI) with the antibody ersodetug (RZ358).

• Two late-stage Phase 3 programs target congenital and tumor-related HI.

• Expanded Access Program shows compelling real-world patient benefit.

• Global market opportunity exceeds $1 billion, with potential for further expansion.

• $152 million in cash provides runway to mid-2027.

Clinical programs and milestones

• Phase 3 sunRIZE study for congenital HI expects topline data in December 2025.

• Phase 3 upLIFT study for tumor HI expects topline data in the second half of 2026.

• Both studies are global, multi-center, and registrational.

• Phase 2b RIZE study showed up to 90% improvement in hypoglycemia metrics at top doses.

• Ersodetug has received Breakthrough Therapy, PRIME, Innovation Passport, and Orphan Drug designations.

Disease background and unmet need

• Congenital HI affects 1 in 22,000 US births, with 50% of children developing neurological deficiencies.

• No approved chronic therapy for congenital HI; current options have poor efficacy and significant side effects.

• Tumor HI includes islet cell and non-islet cell tumors, both with high morbidity and limited treatment options.

• Standard of care therapies are often ineffective or poorly tolerated in both indications.